Recent studies have implicated glycoconjugates on the membrane of growth cones as the necessary markers and intermediaries for axonal recognition, axonal motility, and pathway development. One such glycoconjugate, glycoprotein 93 (gp93), has been characterized, but the relative distribution of gp93 has yet to be described for the embryonic brain. In this study, the anatomical distribution of gp93 has been analyzed at embryonic day 15 (E15) and E18, and on postnatal day 3 in the rat by using a polyclonal gp93 antibody. Furthermore, fetal brain tissue transplanted into the adult rat eye has been tested for gp93 immunoreactivity, since central noradrenergic neurons in brainstem transplants are known to provide a continuous source of growing axons, even in adult tissue. In general, a greater abundance of gp93 immunoreactivity is apparent in the earlier embryonic stages (E15 and E18), whereas less is seen in the postnatal brain. The regions showing unique dispersal patterns of gp93 are the neuroepithelium, cerebral cortex, septo-hippocampal pathways, brainstem, and midbrain. This study has therefore focused on these areas and found implications for gp93 distribution appearing in the early development of specific neuronal pathways. Moreover, axons stain densely for gp93 within brain tissue transplants. The presence of gp93 in areas of extensive axonal outgrowth in the normal brain and in transplants suggests that this antibody is used as an early marker for axonal growth. Furthermore, gp93 might be used to map normal development in order to improve our understanding of diseases arising from developmental abnormalities.